novartis q4 - Search News

Novartis beats Q4 earnings consensus

The Motley Fool on MSN · 5h

Novartis Ag (NVS) Q4 2024 Earnings Call Transcript

Operator instructions] The conference is being recorded. [Operator instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.

Novartis beats Q4 earnings consensus as drug sales surge

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.

YAHOO!Finance · 4h

Novartis Posts Q4 Earnings and Sales Beat, Shares Gain

NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.

11h

Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...

9h

Novartis Q4 Core EPS Beats Market, Hikes Dividend; Sees Growth In FY25; Stock Up

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

6hon MSN

Novartis delays Phase 3 readout for Ionis heart drug

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read ...

7hon MSN

Novartis has cash for a big pharma deal—but here’s why it’s not buying

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

10h

Balanced Caution: Novartis’s Strong Q4 Performance Amidst Growth Uncertainties

J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results